Ajanta Pharma Limited
AJANTPHARM
Classement en actions
#3721
Established in 1973 and headquartered in Mumbai, India, Ajanta Pharma Limited... Established in 1973 and headquartered in Mumbai, India, Ajanta Pharma Limited operates as a specialized pharmaceutical enterprise. This company, along with its subsidiaries, is dedicated to the development, manufacturing, and commercialization of finished dosage forms. Its extensive product range caters to numerous therapeutic categories, such as anti-infectives (antibiotic, anti-malarial), chronic disease management (anti-diabetic, cardiology), women's health (gynecology), pediatrics, respiratory ailments, general health, dermatology, ophthalmology, and pain management. Notable products include multivitamins, antibiotics, eye drops, and cough syrups. Ajanta Pharma boasts a substantial international footprint, operating across India, Africa, other parts of Asia, the United States, and additional global markets. Furthermore, it supplies its pharmaceutical offerings to various government entities, including armed forces, public hospitals, and governmental procurement departments.
Prix de l'action
$35.98
Dernière synchronisation: 2026-10-21
Capitalisation boursière
$4.50B
Changement (1 jour)
-1.18%
Changement (1 an)
29.38%
Pays
IN
Échange Ajanta Pharma Limited (AJANTPHARM)
Catégorie
Healthcare
Revenus pour Ajanta Pharma Limited (AJANTPHARM)
Revenus en Jun 2026 TTM : $637.45M
Selon les derniers rapports financiers de Ajanta Pharma Limited, le chiffre d'affaires actuel de l'entreprise (TTM) est de $637.45M. En 2024, l'entreprise a réalisé un chiffre d'affaires de $504.74M une augmentation par rapport à le chiffre d'affaires de l'année 2023, qui était de $455.42M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Ajanta Pharma Limited de 2005 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $637.45M | 17.29% |
| 2025 | $543.47M | 7.67% |
| 2024 | $504.74M | 10.83% |
| 2023 | $455.42M | 5.26% |
| 2022 | $432.64M | 11.24% |
| 2021 | $388.92M | 14.37% |
| 2020 | $340.05M | 17.10% |
| 2019 | $290.39M | -8.20% |
| 2018 | $316.32M | 7.04% |
| 2017 | $295.52M | 14.66% |
| 2016 | $257.74M | 10.53% |
| 2015 | $233.19M | 18.34% |
| 2014 | $197.05M | 16.14% |
| 2013 | $169.67M | 27.01% |
| 2012 | $133.59M | 17.92% |
| 2011 | $113.29M | 24.79% |
| 2010 | $90.78M | 31.92% |
| 2009 | $68.81M | -10.99% |
| 2008 | $77.31M | 29.89% |
| 2007 | $59.52M | 15.41% |
| 2006 | $51.57M | 13.41% |
| 2005 | $45.48M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 937.20% |
IN
|
